Lurasidone in schizophrenia: new information about dosage and place in therapy

Advances in Therapy
Leslie Citrome


Lurasidone is a newer "atypical" or "secondgeneration" antipsychotic that has received regulatory approval in the US and Canada for the treatment of schizophrenia. Recent changes in lurasidone product labeling include an expansion of the recommended dose range from 40-80 mg/day to 40-160 mg/day, administered once-daily with food. The recommended starting dose is 40 mg/day. Initial dose titration is not required. Efficacy for the treatment of acute episodes of schizophrenia was established in five, 6-week, fixed-dose, randomized, placebo-controlled trials. Additional short-term studies in patients with schizophrenia include a 3-week, randomized, double-blind trial comparing lurasidone with ziprasidone on safety and tolerability outcomes, and a 6-week, randomized, open-label switch study. Available long-term data includes a 12-month, doubleblind safety and tolerability study comparing lurasidone with risperidone; a 6-month, openlabel extension study for one of the shortterm registration studies where patients were initially randomized to receive lurasidone, olanzapine, or placebo; and a 12-month, doubleblind extension study comparing lurasidone with quetiapine extended-release after having received lurasidone, quetiapine extended...Continue Reading


Nov 20, 2015·Drug Development and Industrial Pharmacy·Yanfei MiaoPingkai Ouyang
May 21, 2016·Pharmacological Reports : PR·Rafał R JaeschkeWojciech Datka
Oct 7, 2014·Journal of Clinical Psychopharmacology·Gabor P MolnarMaria C Catalano
Jun 20, 2018·Clinical Pharmacokinetics·Massimo Carlo MauriAlfredo Carlo Altamura
Oct 28, 2017·Annals of General Psychiatry·Jonathan M MeyerAntony Loebel


Jun 6, 2009·The Journal of Clinical Psychiatry·Mitsutaka NakamuraAntony Loebel
Aug 12, 2009·Advances in Therapy·Leslie Citrome
Sep 29, 2009·Expert Opinion on Investigational Drugs·Jonathan M MeyerEdward Schweizer
Dec 24, 2010·Clinical Schizophrenia & Related Psychoses·Leslie Citrome
Jun 17, 2011·The American Journal of Psychiatry·Herbert Y MeltzerAntony Loebel
Mar 1, 2012·Expert Review of Neurotherapeutics·Joshua T Kantrowitz, Leslie Citrome
Mar 8, 2012·International Clinical Psychopharmacology·Leslie CitromeAntony Loebel
Aug 21, 2012·Psychopharmacology·Masaaki OgasaJohn Guarino

Related Concepts

Metabolic Process, Cellular
Antipsychotic Effect
Bipolar Disorder
Parkinsonian Disorders
Adverse Event

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here